Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ: REGN · Real-Time Price · USD

834.04

+7.40 (0.90%)

At close: Aug 21, 2026, 4:00 PM EDT

838.10

+4.06 (0.49%)

After-hours: Aug 21, 2026, 7:58 PM EDT

Regeneron Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 21, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	83,283	79,193	76,639	93,403	77,057	66,029
Market Cap Growth	32.96%	3.33%	-17.95%	21.21%	16.70%	29.49%
Enterprise Value	68,167	63,170	61,056	80,414	66,767	57,309
Last Close Price	834.04	768.90	705.67	870.08	714.75	625.62

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 21, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	20.63	17.58	17.37	23.63	17.76	8.18
Forward PE	13.72	17.11	15.19	19.36	17.29	11.00
PS Ratio	5.36	5.52	5.40	7.12	6.33	4.11
PB Ratio	2.64	2.53	2.61	3.60	3.40	3.52
P/TBV Ratio	2.74	2.64	2.72	3.75	3.54	3.52
P/FCF Ratio	22.15	19.41	20.91	24.10	17.42	10.11
P/OCF Ratio	17.79	15.91	17.34	20.33	15.37	9.32
PEG Ratio	1.16	2.93	0.95	4.75	5.86	5.17

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 21, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
EV/Sales Ratio	4.39	4.40	4.30	6.13	5.49	3.57
EV/EBITDA Ratio	14.50	14.88	13.19	17.28	12.51	6.18
EV/EBIT Ratio	16.33	17.06	14.73	19.00	13.37	6.37
EV/FCF Ratio	18.13	15.48	16.66	20.75	15.09	8.78

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 21, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Debt / Equity Ratio	0.09	0.10	0.10	0.11	0.12	0.14
Debt / EBITDA Ratio	0.57	0.69	0.63	0.60	0.52	0.29
Debt / FCF Ratio	0.72	0.73	0.80	0.72	0.63	0.41
Net Debt / Equity Ratio	-0.48	-0.51	-0.51	-0.52	-0.51	-0.52
Net Debt / EBITDA Ratio	-3.21	-3.74	-3.23	-2.89	-2.17	-1.06
Net Debt / FCF Ratio	-4.02	-3.89	-4.09	-3.47	-2.61	-1.51
Asset Turnover	0.39	0.37	0.40	0.42	0.45	0.76
Inventory Turnover	2.74	2.53	2.51	2.51	2.37	2.74
Quick Ratio	2.63	3.28	3.86	4.82	4.16	2.98
Current Ratio	3.34	4.13	4.73	5.69	5.06	3.56
Return on Equity (ROE)	14.04%	14.87%	15.95%	16.26%	20.94%	54.21%
Return on Assets (ROA)	6.53%	5.91%	7.31%	8.49%	11.42%	26.39%
Return on Invested Capital (ROIC)	13.50%	13.04%	18.58%	22.38%	26.65%	60.13%
Return on Capital Employed (ROCE)	11.50%	10.20%	12.30%	14.30%	19.20%	41.80%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 21, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Earnings Yield	5.20%	5.69%	5.76%	4.23%	5.63%	12.23%
FCF Yield	4.52%	5.15%	4.78%	4.15%	5.74%	9.89%
Dividend Yield	0.45%	0.46%	-	-	-	-
Payout Ratio	9.15%	8.22%	-	-	-	-
Buyback Yield / Dilution	4.76%	5.65%	-1.23%	-0.18%	-1.16%	2.52%
Total Shareholder Return	5.21%	6.11%	-1.23%	-0.18%	-1.16%	2.52%

SEC Filings: 10-K · 10-Q